. The phosphorothioate backbones of AONs also avert renal clearance [38], resulting in
. The phosphorothioate backbones of AONs also prevent renal clearance , resulting within a extended serum half-life and uptake by most of tissues. Phase 3 clinical trials are presently ongoing…